Teva Pharmaceutical Industries Pre-Paid Expenses 2010-2024 | TEVA
Teva Pharmaceutical Industries pre-paid expenses from 2010 to 2024. Pre-paid expenses can be defined as a current asset created by prepayment of costs and expenses for which the benefits will occur at a future date.
- Teva Pharmaceutical Industries pre-paid expenses for the quarter ending September 30, 2024 were $1.127B, a 3.51% decline year-over-year.
- Teva Pharmaceutical Industries pre-paid expenses for 2023 were $1.255B, a 8% increase from 2022.
- Teva Pharmaceutical Industries pre-paid expenses for 2022 were $1.162B, a 8.09% increase from 2021.
- Teva Pharmaceutical Industries pre-paid expenses for 2021 were $1.075B, a 13.76% increase from 2020.
Teva Pharmaceutical Industries Annual Pre-Paid Expenses
(Millions of US $) |
| 2023 |
$1,255 |
| 2022 |
$1,162 |
| 2021 |
$1,075 |
| 2020 |
$945 |
| 2019 |
$870 |
| 2018 |
$899 |
| 2017 |
$1,100 |
| 2016 |
$1,629 |
| 2015 |
$910 |
| 2014 |
$ |
| 2013 |
$ |
| 2012 |
$ |
| 2011 |
$ |
| 2010 |
$ |
| 2009 |
$ |
Teva Pharmaceutical Industries Quarterly Pre-Paid Expenses
(Millions of US $) |
| 2024-09-30 |
$1,127 |
| 2024-06-30 |
$1,096 |
| 2024-03-31 |
$1,336 |
| 2023-12-31 |
$1,255 |
| 2023-09-30 |
$1,168 |
| 2023-06-30 |
$1,228 |
| 2023-03-31 |
$1,253 |
| 2022-12-31 |
$1,162 |
| 2022-09-30 |
$1,045 |
| 2022-06-30 |
$1,052 |
| 2022-03-31 |
$1,064 |
| 2021-12-31 |
$1,075 |
| 2021-09-30 |
$1,066 |
| 2021-06-30 |
$1,022 |
| 2021-03-31 |
$942 |
| 2020-12-31 |
$945 |
| 2020-09-30 |
$895 |
| 2020-06-30 |
$956 |
| 2020-03-31 |
$977 |
| 2019-12-31 |
$870 |
| 2019-09-30 |
$976 |
| 2019-06-30 |
$1,069 |
| 2019-03-31 |
$969 |
| 2018-12-31 |
$899 |
| 2018-09-30 |
$911 |
| 2018-06-30 |
$1,104 |
| 2018-03-31 |
$1,138 |
| 2017-12-31 |
$1,100 |
| 2017-09-30 |
$1,203 |
| 2017-06-30 |
$871 |
| 2017-03-31 |
$960 |
| 2016-12-31 |
$1,629 |
| 2016-09-30 |
|
| 2016-06-30 |
|
| 2016-03-31 |
|
| 2015-12-31 |
$910 |
| 2015-09-30 |
|
| 2015-06-30 |
|
| 2015-03-31 |
|
| 2014-12-31 |
|
| 2014-09-30 |
|
| 2014-06-30 |
|
| 2014-03-31 |
|
| 2013-12-31 |
|
| 2013-09-30 |
|
| 2013-06-30 |
|
| 2013-03-31 |
|
| 2012-12-31 |
|
| 2012-09-30 |
|
| 2012-06-30 |
|
| 2012-03-31 |
|
| 2011-12-31 |
|
| 2011-09-30 |
|
| 2011-06-30 |
|
| 2011-03-31 |
|
| 2010-12-31 |
|
| 2010-09-30 |
|
| 2010-06-30 |
|
| 2010-03-31 |
|
| 2009-12-31 |
|
| 2009-09-30 |
|
| 2009-06-30 |
|
| 2009-03-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$19.350B |
$15.846B |
|
Teva Pharmaceutical Industries Limited is a global pharmaceutical company that develops, manufactures, and markets both branded and generic drugs, as well as active pharmaceutical ingredients in North America, Europe, Latin America, India, and Israel. Teva's generic product portfolio includes tablets, capsules, liquids, ointments, creams, liquids, injectables, and inhalants. The company's branded products include Copaxone, Austedo, respiratory products like ProAir and Qvar and Ajovy. Teva operates through three segments, North America, Europe and International Markets, each of which includes generics, specialty and over-the-counter products. Teva acquired Allergan's generics business Actavis Generics. The company also acquired Allergan's Anda Inc. Teva acquired Auspex Pharmaceuticals and Barr. Teva has strengthened its position in Europe through its acquisition of Germany's second largest generics producer, ratiopharm.
|
